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To identify the novel genes involved in lipid metabolism and lipid droplet formation that may play
important roles in Hepatitis C virus (HCV) propagation, we have screened the small interfering RNA
library using cell culture derived HCV (HCVcc)-infected cells. We selected and characterized the gene
encoding farnesyl-diphosphate farnesyltransferase 1 (FDFT1). siRNA-mediated knockdown of FDFT1
impaired HCV replication in both subgenomic replicon and HCVcc infected cells. Moreover, YM-
53601, an inhibitor of FDFT1 enzyme activity, abrogated HCV propagation. HCV infection increased
FDFT1 protein level but not FDFT1 mRNA level. These results suggest that HCV may modulate FDFT1
protein level to facilitate its own propagation.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatitis C virus (HCV) is a major etiologic agent of chronic liver
disease [1]. Chronic HCV infection often progresses to cirrhosis and
hepatocellular carcinoma (HCC). Approximately 170 million people
worldwide are chronically infected with HCV [2]. HCV is an envel-
oped virus and belongs to the genus Hepacivirus within the Flavivi-
ridae family [3]. HCV has been classiﬁed into 7 genotypes and each
genotype is divided into many subtypes. HCV is a single-stranded
positive sense RNA virus and its genome is 9.6 kb in length. The
genome contains highly structured untranslated regions (UTR) at
the 50 and 30 ends and encodes a polyprotein that is processed into
10 mature proteins. The polyprotein is cleaved by both host and
viral proteases to produce 3 structural (core, E1 and E2) and 7
non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B)
proteins [4].
HCV infection often accompanies hepatic steatosis, and the
accumulation of lipid droplets in hepatocytes is the distinct feature
of HCV infection. More than 70% of patients infected with genotype
3 and 50% of patients infected with other genotypes accompanyliver steatosis as a complication [5]. Cellular lipids are known to
play a crucial role in HCV life cycle contributing to assembly,
release, and infectivity of HCV [6]. Furthermore, HCV modulates
host cellular lipid metabolism to enhance virion assembly and
release [7–9]. Cholesterol is the major component of both lipid
droplet and lipoprotein with triglyceride [10,11]. Cholesterol bio-
synthesis is important for the life cycle of Flavivirus, including
West Nile virus, Japanese encephalitis virus, and dengue virus
[12–14]. The HCV life cycle is associated with cholesterol metabo-
lism [15–17].
Farnesyl-diphosphate farnesyltransferase 1 (FDFT1) is a 47 kDa
membrane associated enzyme [18–20] and plays a critical role in
directing intermediates produced from mevalonate to either non-
sterol pathway or cholesterol synthetic pathway. FDFT1 catalyzes
a two-step reaction in which two molecules of farnesyl diphos-
phate (FPP) are converted into one molecule of squalene. In the
ﬁrst step, a molecule of inorganic diphosphate (PPi) and a proton
are eliminated from farnesyl pyrophosphate to produce carbocat-
ion. And then presqualene is produced by double bond connection
between carbocation and adjacent farnesyl pyrophosphate. In the
second step, the second PPi is eliminated from presqualene and
then squalene is produced by head-to-head linking after reduction
with NADPH [21–23]. FDFT1 is involved in propagation of some
viruses of Flaviviridae family. Zaragozic acid A, an inhibitor FDFT1,
could inhibit dengue virus replication [14]. It has been also
reported that cholesterol metabolism-associated genes were al-
tered in HCV-infected liver [24,25]. However, it is unknown
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regulate HCV propagation. In this study, we demonstrated that siR-
NA mediated knockdown of FDFT1 expression impaired HCV prop-
agation. In addition, treatment of YM-53601 also inhibited HCV
propagation in HCV-infected cells. Collectively, these data demon-
strate that FDFT1 is the key regulator of HCV propagation and may
contribute to HCV-mediated pathogenesis.
2. Materials and methods
2.1. Cell culture
Huh7.5 cells were grown in Dulbecco’s modiﬁed Eagle’s med-
ium (DMEM) supplemented with 10% fetal bovine serum, 1%
non-essential amino acid, and 1% penicillin–streptomycin in 5%
CO2 at 37 C. HCV subgenomic replicon cells were grown in DMEM
supplemented with 10% fetal bovine serum and 500 lg/ml G418.
2.2. Chemical and antibodies
YM-53601, an inhibitor of FDFT1, was purchased from Cayman-
chem (MI, U.S.A). Antibodies were purchased from the following
sources: FDFT1 antibodies from Epitomics; beta actin antibodies
from Santa Cruz. HCV core, NS3, and NS5A antibodies were
described elsewhere [26].
2.3. Generation of HCVcc
Jc1 and JFH1-Luc constructs were kindly provided by Dr. Ralf
Bartenschlager. Cell culture derived HCV (HCVcc) was generated
as described previously [27].
2.4. MTT assay
Huh7.5 cells either transfected with siRNAs or treated with
FDFT1 inhibitor were incubated with 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (Sigma) for
2 h at 37 C. Cell viability was determined as we reported previ-
ously [26].
2.5. RNA interference
We selected 114 genes that control lipid metabolism and lipid
droplet formation, and siRNA targeting these genes were pur-
chased from Dharmacon (Lafayette, CO). Each pool consists of 4
siRNA duplexes designed to target different regions of the same
target mRNA sequence. The universal negative control siRNA and
siRNA targeting 50UTR of Jc1 (50-CCU CAA AGA AAA ACC AAA
CUU-30) as a positive control were also purchased from Dharma-
con. siRNA targeting ApoE (50-AGACAGAGCCGGAGCCCGA-30) [28]
was purchased from Bioneer (Korea). siRNA transfection was per-
formed by using a Lipofectamine RNAiMax reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol.
2.6. Immunoblot analysis
Cells were washed twice with phosphate-buffered saline (PBS)
and were lysed in RIPA buffer (50 mM Tris–HCl [pH 7.5], 1% NP-
40, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1 mM Na3VO4, and
1 mM PMSF) for 15 min on ice, and centrifuged at 12000 rpm for
10 min at 4 C. The supernatant was collected and equal amounts
of protein were subjected to SDS–PAGE and electrotransferred to
a nitrocellulose membrane. The membrane was blocked in TBS/
Tween (20 mM Tris–HCl (pH 7.6), 500 mM NaCl, and 0.25% Tween
20) containing 5% non-fat dry milk for 1 h and then incubated withthe indicated antibodies. Proteins were detected using an ECL kit
(Abfrontier).
2.7. Luciferase reporter assay
Huh7.5 cells were electroporated with 10 lg of in vitro-tran-
scribed JFH1-luc RNA. At 48 h after electroporation, cells were har-
vested and then luciferase assays were performed using a Gloma
20/20 luminometer (Promega) as described previously [26].
2.8. Quantitative real-time PCR
Total RNAs were isolated from cells using RiboEX reagent
(GeneAll) according to the manufacturer’s instructions. cDNAs
were synthesized by using cDNA synthesis kit (Toyobo) according
to the manufacturer’s instructions and quantitative real-time PCR
(qPCR) was performed using following primers: (sense) 50-TTA
GTA TGA GAG TCG TAC AGC CTC CAG-30 and (antisense) 50-GGC
ATA GAG TGG GTT TAT CCA AGA AAG G-30 for HCV; (sense) 50-
TGA CAG CAG TCG GTT GGA GCG-30 and (antisense) 50-GAC TTC
CTG TAA CAA CGC ATC TCA TA-30 for beta-actin; (sense) 50-ACC
ATC ATC CGT GAC TAT CTG-30 and (antisense) 50-CTT CTT AAC
ATA CCT GCT GCT CCA A-30 for FDFT1; (sense) 50-TTC CTG GCA
GGA TGC CAG GC-30 and (antisense) 50-GGT CAG TTG TTC CTC
CAG TTC-30 for ApoE [29]. qPCR experiments were performed using
an IQ5 multicolor Real-time PCR Detection system (Bio-Rad Labo-
ratories, Hercules, CA) under the following conditions: 15 min at
95 C followed by 40 cycles of 95 C for 20 s, 55 C for 20 s, and
72 C for 20 s. Seventy-one cycles of 10 s, with 0.5 C temperature
increments from 60 to 95 C, were used for the melting curves. The
standards were run in parallel with the samples and the absolute
RNA copy number was determined based on standard curve.
2.9. Immunoﬂuorescence assay
Huh7.5 cells cultured on glass slide were ﬁxed in 4% parafor-
maldehyde for 30 min at room temperature and permeabilized
with 0.1% Triton X-100 in PBS for 10 min. Cells were blocked with
0.5% BSA for 1 h and then incubated overnight with a rabbit anti-
NS5A antibody at 4 C. After three washes with PBS, cells were
incubated with tetramethylrhodamine isothiocyanate (TRITC)-con-
jugated donkey anti-rabbit IgG (Jackson Imunoresearch Laborato-
ries) for 1 h at room temperature. After three washes with PBS,
cells were analyzed using the Zeiss LSM 700 laser confocal micros-
copy system (Carl Zeiss, Inc., Thornwood, NY).
3. Results
3.1. FDFT1 is a host factor required for HCV propagation
Host cellular lipid metabolism is essential for the efﬁcient reg-
ulation of the HCV life cycle. To identify the host genes involved in
lipid metabolism and lipid droplet formation that may play
important roles in HCV propagation, we generated a set of siRNA
library targeting 114 genes. The mixture of four different siRNA
sequences was used to minimize any off-target effects. HCVcc-
based primary screening was performed using a siRNA library.
Each screen was performed in triplicates. siRNAs that altered
the HCV particle release by an average twofold compared to neg-
ative control were selected as hits. From the 114 siRNA pools tar-
geting lipid metabolism, we identiﬁed candidate hits by primary
screening, and secondary screening was carried out based on
HCV replication and release by qPCR. Among candidate genes,
FDFT1 (also known as squalene synthase) was selectively chosen
for further characterization because silencing of this gene showed
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the effect of FDFT1 on HCV propagation, we examined the HCV
expression level in FDFT1 siRNA transfected cells. As a positive
control, we used a siRNA targeting 50UTR of HCV RNA. As shown
in Fig. 1B, HCV protein expression levels were dramatically de-
creased in cells treated with positive-control siRNA (lane 2). Like-
wise, HCV protein expression levels were prominently decreased
in FDFT1 knockdown cells (Fig. 1B, lane 3). Since apolipoproteinA
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but not the intracellular HCV RNA level, was signiﬁcantly de-
creased in ApoE knockdown cells. Nevertheless, when naïve
Huh7.5 cells were infected with culture supernatant harvested
from Fig. 1C, intracellular HCV RNA levels were signiﬁcantly de-
creased in both FDFT1 and ApoE knockdown cells (Fig. 1E). These
data suggest that FDFT1 may not be involved in the assembly and
release stage of the HCV life cycle. To rule out off-target effects,
we investigated the individual effects of the four siRNAs from
the siRNA pools on HCV replication. Huh7.5 cells transfected with
negative, positive, or four different FDFT1 siRNA individually were
infected with Jc1 and knockdown efﬁciencies were analyzed.Fig. 2A showed that all four individual siRNA signiﬁcantly im-
paired FDFT1 mRNA expression. When Huh7.5 cells were transfec-
ted with these siRNAs, intracellular HCV RNA levels were
signiﬁcantly reduced in HCV infected cells (Fig. 2B). We further
showed that each of four siRNAs independently impaired HCV
protein expression level, further conﬁrmed the speciﬁcity of siRNA
targeting FDFT1 (Fig. 2C). To examine the infectivity of HCV parti-
cles released from the FDFT1 knockdown cells, naïve Huh7.5 cells
were infected with culture supernatant harvested from 2A. Total
cell lysates harvested at two days postinfection were analyzed
for viral protein expression levels. As demonstrated in Fig. 2D,
viral protein expression levels were also decreased by over
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1818 E.-M. Park et al. / FEBS Letters 588 (2014) 1813–182080%. We showed that infectious virus particle levels were
decreased over 50% by treatment of each of all four siRNAs
(Fig. 2E), demonstrating that these siRNAs impaired HCV infectiv-
ity. Knockdown of FDFT1 did not affect cell viability (Fig. 2F),
indicating that the impairment of HCV propagation by siRNA
knockdown was not caused by cellular cytotoxicity.3.2. FDFT1 inhibitor impairs HCV propagation
To further verify the requirement of FDFT1 in the HCV life cycle,
we investigated the effect of FDFT1 inhibitor, YM-53601, on HCV
propagation. Huh7.5 cells infected with Jc1 were treated with
either DMSO or various concentrations of YM-53601. As shown
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inhibitor, and that the inhibition occurred in a dose-dependent
manner. We also demonstrated that HCV protein expression levels
were decreased in a dose dependent manner of FDFT1 inhibitor in
HCV infected cells (Fig. 3B). To investigate the infectivity of re-
leased HCV particle in inhibitor treated cells, naïve Huh7.5 cells
were infected with culture supernatant harvested from 3A and
then infectivity was determined by focus forming assay. Fig. 3C
showed that HCV infectivity was signiﬁcantly decreased in a dose
dependent manner of YM-53601. To further conﬁrm the role of
FDFT1 in HCV propagation, we performed immunoﬂuorescence as-
say using Jc1 infected cells. As shown in Fig. 3D, treatment of YM-
53601 markedly reduced HCV propagation as determined by NS5A
expression. We veriﬁed that treatment of YM-53601in Huh7.5 cells
did not induce cellular cytotoxicity (Fig. 3E). Collectively, these
data indicate that FDFT1 enzyme activity plays a crucial role in
HCV propagation.
3.3. FDFT1 is involved in the replication stage of the HCV life cycle
To investigate the possible involvement of FDFT1 in the entry
step of the HCV life cycle, we analyzed the effect of FDFT1 using
YM-53601 in HCV RNA transfected cells. Huh7.5 cells electropora-
ted with in vitro-transcribed Jc1 RNA were treated with YM-53601.
As shown in Fig. 4A, both intracellular HCV RNA and protein
expression levels were remarkably decreased by FDFT1 inhibitor.
We also investigated the HCV infectivity of culture supernatant
harvested from Fig. 4A and conﬁrmed that HCV infectivity was also
signiﬁcantly decreased by FDFT1 inhibitor (Fig. 4B). These results
indicate that FDFT1 is involved in the post-entry step of the HCV
lifecycle. To further conﬁrm the involvement of FDFT1 in HCV
replication, we performed luciferase assay by using the JFH1-luc
reporter construct. Huh7.5 cells were electroporated with JFH1-
luc RNA and then were treated with YM-53601. Fig. 4C showed
that luciferase activity was signiﬁcantly decreased at 48 h and this
inhibitory activity was further increased at 72 h after inhibitor
treatment. We showed that 5 lM of YM-53601 suppressed lucifer-
ase activity by 50% as compared to DMSO control and luciferase
activity was decreased in a dose-dependent manner (Fig. 4D). Tofurther investigate the involvement of FDFT1 in the replication
stage of the HCV life cycle, we transfected HCV subgenomic repli-
con cells with either negative control siRNA or FDFT1 siRNA and
analyzed the HCV RNA levels by qPCR. As demonstrated in
Fig. 4E, knockdown of FDFT1 resulted in signiﬁcant decrease of
HCV RNA levels in subgenomic replicon cells derived from both
genotypes 1b and 2a. Since HCV subgenomic replicon is unable
to infect or assemble in cells, this result veriﬁes that FDFT1 is in-
volved in the replication step of the HCV life cycle.
3.4. HCV infection increases FDFT1 protein level
To investigate whether FDFT1 expression is altered by HCV
infection, we infected Huh7.5 with Jc1 and monitored the FDFT1
protein expression level up to 12 days postinfection. As shown in
Fig. 5A, FDFT1 protein level increased on day four in HCV-infected
cells when compared to mock infected cells and maintained high
levels up to day 12 postinfection. We noticed that FDFT1 mRNA
levels were not signiﬁcantly altered by HCV infection (Fig. 5B).
These data indicate that HCV infection may stabilize FDFT1 protein
to facilitate its own propagation.
4. Discussion
Cellular lipid metabolism and cholesterol biosynthesis play a
crucial role in the HCV life cycle contributing to assembly, release,
and infectivity of HCV [8]. To investigate the key genes that control
the lipid metabolism involved in HCV replication, we used siRNAs
to selectively knockdown the protein involved in the major steps of
host lipid metabolism. siRNAs targeting FDFT1 were found to inhi-
bit HCV replication in Jc1 infected cells. FDFT1 is the enzyme that
plays a critical role in cholesterol biosynthetic pathway. FDFT1 di-
rects farnesyl diphosphate to either a non-sterol pathway or a ste-
rol synthetic pathway. Activated FDFT1 facilitates cholesterol
biosynthesis by catalyzing the conversion of farnesyl diphosphate
into squalene [21–23]. It has been previously reported that the
cholesterol biosynthetic pathway is required for the life cycle of
Flavivirus, including the West Nile virus, Japanese encephalitis
virus, and the dengue virus [12–14]. The involvement of
1820 E.-M. Park et al. / FEBS Letters 588 (2014) 1813–1820cholesterol metabolism in HCV propagation has also been reported
previously [16,17]. HCV replication requires a geranylgeranylation
of the host protein. The disruption of HCV replication by treatment
with lovastatin, an inhibitor of HMG CoA reductase, was rescued by
exogenous supplementation of geranylgeraniol, but not with farne-
sol [30]. However, the detailed mechanism of cholesterol metabo-
lism in HCV propagation remains unclear.
Here we showed that siRNA mediated knockdown of FDFT1 re-
sulted in signiﬁcant decreases of intracellular HCV RNA and protein
expression levels. Moreover, we also demonstrated that HCV infec-
tivity was signiﬁcantly decreased in FDFT1 knockdown cells. These
data indicate that FDFT1 is required for HCV propagation. To
further verify the involvement of FDFT1 in HCV propagation, we
investigated the effect of the FDFT1 enzyme-speciﬁc inhibitor,
YM-53601, on HCV propagation. Indeed, YM-53601 efﬁciently
inhibited HCV replication at 1 lM concentration in HCV infected
cells. HCV infectivity was also signiﬁcantly reduced by the treat-
ment of the FDFT1 inhibitor. The inhibitory activity of YM-53601
on HCV replication was further veriﬁed by the immunoﬂuores-
cence assay.
To investigate whether FDFT1 was involved in the viral entry
step of the HCV life cycle, Huh7.5 cells were electroporated with
in vitro-transcribed Jc1 RNA and treated with YM-53601. The treat-
ment of YM-53601 in Huh7.5 cells electroporated with HCV RNA
resulted in signiﬁcant decreases of intracellular HCV RNA level,
protein expression level, and HCV infectivity. We conﬁrmed this
result by luciferase assay. We showed that the treatment of
YM-53601 in Huh7.5 cells electroporated with JFH1-luc RNA sig-
niﬁcantly decreased HCV propagation. We further demonstrated
that knockdown of FDFT1 signiﬁcantly decreased HCV RNA level
in subgenomic replicon cells. Since HCV subgenomic replicon is
unable to infect or assemble in cells, these data indicate that FDFT1
may be a host factor involved in the replication step of the HCV life
cycle.
We also showed that the FDFT1 expression level was increased
in HCV infected cells. Of note, FDFT1 mRNA levels were not signif-
icantly altered by HCV infection. These data indicate that HCV
infection may stabilize FDFT1 protein level to facilitate its own
propagation. However, how HCV usurps cellular FDFT1 for its
own replication needs further investigation. Collectively, these
data highlight the critical role of FDFT1 as a host factor for HCV
propagation and thus it may be an attractive target for therapeutic
intervention.
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